Abstract:Abstract Background: Long-term survivors of childhood cancer experience high rates of patient-reported symptoms and evidence for accelerated molecular aging. Both are established to increase the risk for late-mortality (>5 years from cancer diagnosis). We aim to investigate if accelerated molecular aging mediates the association between symptoms and all-cause late-mortality. Methods: DNA methylation (DNAm)-based aging biomarkers were derived from the DNAm Age Calculator, including epigenetic age acceleration (EAA) using multiple clocks (e.g., GrimAge and PhenoAge) and other DNAm-predicted biomarkers (e.g., DNAmB2M: beta-2-microglobulin, DNAmTL: telomere length) adjusted for age and standardized. Survivors self-reported the presence of 10 symptom domains (cardiac, pulmonary, sensory, motor/movement, nausea, pain, fatigue, memory, anxiety, and depression) that were aggregated into a total symptom burden score. Multiple linear regression tested the association between each aging biomarker and symptom prevalence, adjusting for the age of symptom survey, sex, and cancer treatment exposures. Cox regression tested the association of each aging biomarker or symptom domain with mortality. Aging biomarkers mediation for the symptom-mortality association was assessed by using the Accelerated Failure Time model and the mediation R package. False discovery rate was controlled for multiple testing. Results: Among 2,206 survivors (47% males) who had DNAm measured on (52%) or after the survey, the median duration from the symptom survey to DNA sampling were 0.48 years (IQR: 0.09-4.27 years). EAA_GrimAge was the aging biomarker most closely associated with total symptom burden (beta [95%CI] = 0.576 [0.455, 0.697] years, P=2.89×10-18) and eight of ten domain-specific symptoms except for motor/movement and memory. Seven aging biomarkers (e.g., DNAmB2M: 1.91 [1.48, 2.48], P=1.87×10-5; EAA_GrimAge: HR [95%CI] = 1.17 [1.09, 1.26], P=3.1×10-4 ) and five symptom domains (e.g., pulmonary: 2.54 [1.44, 4.49], P=0.004; cardiac: 2.25[1.28, 3.97], P=0.01; total symptom burden: 1.47 [1.18, 1.82], P=0.0019) were associated with mortality risk. EAA (e.g., EAA_GrimAge) mediated the association between symptoms (cardiac: % mediation =0.13 [0.044, 0.379], P=0.008; pulmonary: 0.186 [0.075, 0.486], P=0.008; and total symptoms: 0.206 [0.078, 0.503], P=0.012) and late mortality. In addition, the association between symptoms and mortality was mediated by DNAmB2M and DNAmTL (e.g., pulmonary: 0.152 [0.046, 0.378], P=0.008; 0.12 [0.031, 0.373], P=0.021). Conclusions: EAA, DNAmB2M and DNAmTL mediated the association between the presence of specific symptom domains and late-mortality, suggesting that accelerated molecular aging may be an underlying biological pathway explaining the associations between symptom burden and mortality. Citation Format: Qian Li, Yue Pan, Xijun Zhang, Noel-Marie Plonski, g Chen, Qian Dong, Kyla Shelton, John Easton, Heather Mulder, Jinghui Zhang, Geoffrey Neale, Emily Walker, Deo Kumar Srivastava, Greg T. Armstrong, Kirsten Ness, I-Chan Huang, Zhaoming Wang. DNA methylation based aging biomarkers mediate the association between patient-reported symptoms and all-cause late-mortality: A report from the St. Jude Lifetime Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6384.

DNA methylation age of blood predicts all-cause mortality in later life

Blood DNA Methylation Sites Predict Death Risk in a Longitudinal Study of 12, 300 Individuals

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing

DNA Methylation-Based Biomarkers of Age Acceleration and All-Cause Death, Myocardial Infarction, Stroke, and Cancer in Two Cohorts: the NAS, and KORA F4

DNA methylation GrimAge strongly predicts lifespan and healthspan

DNAm-based Signatures of Accelerated Aging and Mortality in Blood Are Associated with Low Renal Function.

DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes

Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden

Integrative analysis of clinical and epigenetic biomarkers of mortality

NMR metabolomics-guided DNA methylation mortality predictors

DNA methylation age as a biomarker for cancer

Epigenome-Wide Scans Identify Differentially Methylated Regions for Age and Age-Related Phenotypes in A Healthy Ageing Population

A Longitudinal Study of DNA Methylation As a Potential Mediator of Age-Related Diabetes Risk

DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies

Epigenetic prediction of complex traits and death

Genetic Correlates of Biological Aging and the Influence on Prediction of Mortality

DNA methylation outlier burden, health, and ageing in Generation Scotland and the Lothian Birth Cohorts of 1921 and 1936

Abstract 6384: DNA Methylation Based Aging Biomarkers Mediate the Association Between Patient-Reported Symptoms and All-Cause Late-Mortality: A Report from the St. Jude Lifetime Cohort

DNA methylation outlier burden, health and ageing in Generation Scotland and the Lothian Birth Cohorts of 1921 and 1936